Trials / Terminated
TerminatedNCT01097707
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 414 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- Male
- Age
- 45 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine whether LY500307 helps symptoms of Benign Prostatic Hyperplasia (BPH)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY500307 | Administered orally, daily for 24 weeks |
| DRUG | Placebo | Administered orally, daily for 24 weeks |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
- First posted
- 2010-04-02
- Last updated
- 2019-04-08
- Results posted
- 2019-04-08
Locations
70 sites across 8 countries: United States, Australia, Canada, France, Germany, Greece, Italy, Russia
Source: ClinicalTrials.gov record NCT01097707. Inclusion in this directory is not an endorsement.